LLY is trading 3.7% up at $1244.16 following positive regulatory and reimbursement developments for its core drug portfolio.

  • An EMA panel recommended a broader label for the oncology drug Jaypirca, while the company announced that Zepbound and Foundayo will be available to Medicare patients for $50 per month starting July 1, 2026.

  • These moves significantly strengthen the company's long-term position in the high-growth obesity and oncology markets, supporting increasingly bullish analyst sentiment.